Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Skin Neoplasms 2Melanoma 2Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Leukemia, B-Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1Blood Protein Disorders 1

Interventions

Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4Epoetin Alfa 3Darbepoetin alfa 3Curcumin 3liposomal amphotericin B 2fludarabine phosphate 2Morphine 2Methylprednisolone 2Interferon-alpha 2Filgrastim 2Cyclosporine 2Caspofungin 2Carboplatin 2Bortezomib 2Antilymphocyte Serum 2tanespimycin 1siltuximab 1sargramostim 1pyroxamide 1piperine 1isatuximab 1ibrutinib 1ferrous sulfate 1ferric gluconate 1alethine 1aldesleukin 1Whole-Body Irradiation 1Topotecan 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Monoclonal Gammopathy of Undetermined Significance × Hsp90 inhibitor KU757 × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡